Emalex Biosciences, Inc., announced on Nov. 10, 2021, results from its Phase 2b clinical study (D1AMOND Study) of its drug ecopipam (EBS-101), a dopamine-1 (D1) receptor antagonist, for the treatment of pediatric patients with Tourette syndrome.
The trial included 153 children ages 6 to 18 who participated in a 12-week treatment course at 63 sites across the U.S., Canada and Europe.
“Statistically significant and clinically meaningful results were obtained on this primary endpoint at all timepoints, from Week 4 to Week 12,” the company states.